Monoclonal antibodies

(redirected from Antibody engineering)
Also found in: Medical.

Monoclonal antibodies

Antibody proteins that bind to a specific target molecule (antigen) at one specific site (antigenic site). In response to either infection of immunization with a foreign agent, the immune system generates many different antibodies that bind to the foreign molecules. Individual antibodies within this polyclonal antibody pool bind to specific sites on a target molecule known as epitopes. Isolation of an individual antibody within the polyclonal antibody pool would allow biochemical and biological characterization of a highly specific molecular entity targeting only a single epitope. Realization of the therapeutic potential of such specificity launched research into the development of methods to isolate and continuously generate a supply of a single lineage of antibody, a monoclonal antibody (mAb).

In 1974, W. Köhler and C. Milstein developed a process for the generation of monoclonal antibodies. In their process, fusion of an individual B cell (or B lymphocyte), which produces an antibody with a single specificity but has a finite life span, with a myeloma (B cell tumor) cell, which can be grown indefinitely in culture, results in a hybridoma cell. This hybridoma retains desirable characteristics of both parental cells, producing an antibody of a single specificity that can grow in culture indefinitely.

Generation of monoclonal antibodies through the hybridoma process worked well with B cells from rodents but not with B cells from humans. Consequently, the majority of the first monoclonal antibodies were from mice. When administered into humans as therapeutic agents in experimental tests, the human immune system recognized the mouse monoclonal antibodies as foreign agents, causing an immune response, which was sometimes severe. Although encouraging improvements in disease were sometimes seen, this response made murine (mouse) antibodies unacceptable for use in humans with a functional immune system.

Fueled by advances in molecular biology and genetic engineering in the late 1980s, efforts to engineer new generations of monoclonal antibodies with reduced human immunogenicity have come to fruition. Today there are a number of clonal antibodies approved for human therapeutic use in the United States.

Characterization of the structure of antibodies and their genes laid the foundation for antibody engineering. In most mammals, each antibody is composed of two different polypeptides, the immunoglobulin heavy chain (IgH) and the immunoglobulin light chain (IgL). Comparison of the protein sequences of either heavy of light antibody chain reveals a portion that typically varies from one antibody to the next, the variable region, and a portion that is conserved, the constant region. A heavy and a light chain are folded together in an antibody to align their respective variable and constant regions. The unique shape of the cofolded heavy- and light-chain variable domains creates the variable domain of the antibody, which fits around the shape of the target epitope and confers the binding specificity of the antibody.

Mice genetically engineered to produce fully human antibodies allow the use of established hybridoma technology to generate fully human antibodies directly, without the need for additional engineering. These transgenic mice contain a large portion of human DNA encoding the antibody heavy and light chains. Inactivation of the mouse's own heavy- and light-chain genes forces the mouse to use the human genes to make antibodies. Current versions of these mice generate a diverse polyclonal antibody response, thereby enabling the generation and recovery of optimal monoclonal antibodies using hybridoma technology.

Disease areas that currently are especially amenable to antibody-based treatments include cancer, immune dysregulation, and infection. Depending upon the disease and the biology of the target, therapeutic monoclonal antibodies can have different mechanisms of action. A therapeutic monoclonal antibody may bind and neutralize the normal function of a target. For example, a monoclonal antibody that blocks the activity of the of protein needed for the survival of a cancer cell causes the cell's death. Another therapeutic monoclonal antibody may bind and activate the normal function of a target. For example, a monoclonal antibody can bind to a protein on a cell and trigger an apoptosis signal. Finally, if a monoclonal antibody binds to a target expressed only on diseased tissue, conjugation of a toxic payload (effective agent), such as a chemotherapeutic or radioactive agent, to the monoclonal antibody can create a guided missile for specific delivery of the toxic payload to the diseased tissue, reducing harm to healthy tissue. See Antibody, Antigen, Genetic engineering, Immunology

References in periodicals archive ?
The RAN consortium has developed an automated, antibody engineering pipeline that enables high-throughput generation and validation of high-performance recombinant antibodies, at an unprecedented scale, said James Wells, PhD, one of the founding members of the RAN and a professor of pharmaceutical chemistry in the UCSF School of Pharmacy.
It is now able to offer new services, including antibody humanisation to supplement its antibody engineering, antibody expression and hybridoma sequencing services.
Prior to joining Sutro, he was senior director of antibody engineering at OncoMed Pharmaceuticals, where his team discovered several antibodies for its clinical pipeline.
Designed for fellow researchers working in research and development, the text includes an opening discussion of current advances and future trends in antibody therapeutics, followed by chapters taking readers through the major stages from identification or selection of appropriate targets to antibodies in clinical use: recombinant antigens, antibody libraries, antibody discovery, antibody engineering, antibody preclinical development, and antibody sequence analysis.
This collaboration has great potential for designing superior immunocytokines based on the characteristics of our unique Tribody antibody engineering platform," said Pedro de Noronha Pissarra Ph.
The Company has utilized the many advances made in the fields of molecular biology, oncology, genomics and antibody engineering to build a novel pipeline of product candidates designed to address specific genetic mechanisms involved in cancer growth and development.
Established in 1996 as a spin-off of Dade-Behring, Sunol has made substantial progress in all areas of research and development, establishing its core technology in Tissue Factor and antibody engineering.
Therapeutic Antibody Engineering examines all aspects of engineering monoclonal antibodies and analyses the effect that various genetic engineering approaches will have on candidates of the future.
MedImmune executive vice president Bahija Jallal stated: The cutting-edge technologies developed by Spirogen and ADC Therapeutics complement Med-Immune s innovative antibody engineering capabilities, enabling us to accelerate antibody-drug conjugates into the clinic.
Protein engineering can be defined as a process of developing valuable proteins and modification of antibodies to increase similarity and is called antibody engineering.
Celltech also possesses drug discovery capabilities of exceptional strength, including a leading position in antibody engineering.